Exercise Therapy for PAD Using Mobile Health (Smart MOVE)

Enhanced Home-Based Exercise Therapy for Peripheral Arterial Disease Through Mobile Health and Remote Monitoring

Peripheral artery disease (PAD) is a highly prevalent condition affecting up to 10% of Veterans that leads to loss of walking ability and increased risk of amputation. Veterans have limited access to supervised exercise therapy, a facility-based program proven to improve walking ability in PAD, which is poorly attended due to the inconvenience and cost of attending a 12-week program with multiple weekly sessions. This CDA-2 application will investigate the feasibility of home-based exercise therapy (HBET) delivered using mobile health (mHealth) technologies in Veterans with symptomatic PAD. We will partner with the MOVE! program to deliver HBET through group behavioral coaching and a novel wearable activity monitor in a newly proposed program called Smart MOVE!. There is a clear need to provide effective and convenient alternatives to supervised exercise for Veterans with PAD. This study will provide evidence to proceed with Smart MOVE!, a much-needed patient-centered rehabilitation program for Veterans with PAD.

Study Overview

• Status: Recruiting
• Conditions: Peripheral Artery Disease
• Intervention / Treatment: Behavioral: Performance evaluation; Behavioral: Smart MOVE!; Behavioral: General walking advice

Detailed Description

An estimated 8.5 million Americans (or 7% of US adults) and nearly 10% of veterans are estimated to have peripheral arterial disease (PAD). Significantly debilitating and negatively impacting quality of life, the primary symptom of PAD is claudication (reproducible leg pain with ambulation) that leads to impaired mobility, loss of functional independence, and a heightened risk for amputation. Veterans are at an increased risk of developing symptomatic PAD due to their disproportionately high rates of PAD risk factors such as diabetes, smoking, and hypertension, the most prominent PAD risk factors.

Supervised exercise therapy is proven to decrease claudication and enhance mobility in PAD; however, fewer than 25% of eligible patients enroll. Participation in this facility-based program requires travel to a rehabilitation center 3 times per week for 12-weeks, which can be burdensome and costly for Veterans, many of whom live in rural areas and on fixed incomes. There is, therefore, a need to develop a convenient and effective alternative exercise rehabilitation program for Veterans with PAD, particularly in light of safety considerations now associated with this population's travel to group facilities in the current COVID pandemic.

A promising approach to increase access to exercise rehabilitation for PAD is remote, home-based exercise therapy (HBET). HBET programs combine self-led walking exercises with health coaching and exercise tracking with a wearable activity monitor. Adapting HBET to PAD is difficult, however, due to the added complexity of an exercise prescription that requires the patient to walk until they experience near-maximal leg pain. Even with active coaching, successfully implementing HBET for PAD with long-term adherence has been difficult in the past. The goal is of this study is to leverage newer mobile health (mHealth) tools to adapt HBET for PAD.

This technology-enhanced approach for HBET will be conducted by partnering with a successful VA lifestyle program, MOVE!, which has demonstrated success in achieving sustained weight loss and reduced diabetes onset through lifestyle modification. As increased physical activity is a core element of MOVE!, participation may help increase adherence with HBET for PAD. This newly proposed program, Smart MOVE!, will be a multi-component program featuring a tailored version of MOVE! and a novel mHealth device to improve convenience, access, and adherence to HBET for PAD.

• Study Type: Interventional
• Enrollment (Estimated): 75
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Arash Harzand, MD; Phone Number: 20-5523 (404) 321-6111; Email: Arash.Harzand@va.gov

Study Locations

• United States
  • Georgia
    • Decatur, Georgia, United States, 30033-4004
      • Recruiting
      • Atlanta VA Medical and Rehab Center, Decatur, GA
      • Contact: Arash Harzand, MD; Phone Number: 20-5523 (404) 321-6111; Email: Arash.Harzand@va.gov
      • Principal Investigator: Arash Harzand, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age >40 years
• Eligible Veteran status
• Clinically stable intermittent claudication ( 2 months of Rutherford Class II symptoms, no evidence of chronic limb-threatening ischemia)
• Established PAD diagnosis (abnormal ankle-brachial index or evidence of PAD on prior certified vascular laboratory or radiology imaging)
• Access to safe location to perform walking exercises

Exclusion Criteria:

• Above or below knee amputation

  • critical limb ischemia (rest pain or tissue loss including ulceration or gangrene)
  • inability to walk without a walker
  • wheelchair confinement
  • non-English speaking
  • significant visual impairment that interferes with walking activity
  • hearing impairment that interferes with full study participation
  • unable or unwilling to return to the medical center at the expected visit frequency or unable or unwilling to use the technology required for the intervention
• Individuals whose walking is limited by a condition other than PAD

• Any active cardiac condition including unstable angina

  • unstable atrial or ventricular arrhythmias
  • high-grade heart block without a pacemaker
  • active myopericarditis
  • recent venous thromboembolism
  • or recent abnormal baseline stress test suggesting ischemia
  • other high-risk findings (e.g., drop of systolic blood > 20 mmHg with exercise)
• Presence of Class III NYHA heart failure or CCS III angina.
• Major surgery including lower extremity revascularization or orthopedic surgery during the preceding three months or anticipated in the next nine months

• Major medical illness including lung disease requiring continuous oxygen (patients wearing nighttime oxygen only may still qualify)

  • neurodegenerative disorders such as Parkinson's Disease that impair walking ability
  • cancer requiring treatment in the past 2 years (with exception for non-melanoma skin cancer or if they received treatment for early-stage cancer with an excellent overall prognosis)
• Heart attack, stroke, or coronary artery bypass surgery in the preceding 3 months

• Mental health illness that may interfere with the ability to consent and/or participate in the study, including mini-mental status examination score <24

  • dementia
  • active psychiatric disorder such as schizophrenia or bipolar disorder
  • history of suicidal or homicidal ideation in the preceding six months
  • history of suicidal attempts in the preceding 12 months
  • history of active substance use in the preceding six months that would interfere with study participation (as determined by their primary care or mental health provider)
• Subjects endorsing SI or HI may be eligible for continued participation with monitoring if approved by their primary mental health provider
• Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention
• Currently enrolled in another clinical trial or structured exercise program (i.e., cardiac rehabilitation)
• Deemed to be poorly suited for the study or the study intervention at the discretion of the PI or study staff

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Performance evaluation; Preliminary performance evaluation to refine the Smart MOVE! intervention.	Behavioral: Performance evaluation; Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include: Provider and stakeholder interviews; PAD patient interviews 2) N-of-1 trials to refine the intervention
Active Comparator: Smart MOVE!; Participants will be enrolled in the multi-component Smart MOVE! intervention for 12 weeks.	Behavioral: Smart MOVE!; Multi-component behavioral intervention of PAD consisting of: guideline-directed HBET prescription; active behavioral coaching (via MOVE! program or other); mobile health monitoring
Placebo Comparator: Usual care; Participants will receive general walking advice for 12 weeks.	Behavioral: General walking advice; Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
6-minute walk test	The 6MWT is a well-validated measure of functional capacity and increasingly recognized as a meaningful outcome measure in PAD. Participants will be asked to walk back and forth along a 100-foot hallway for six minutes using standard methods and have their total distance recorded	90 days

Collaborators and Investigators

• Sponsor: VA Office of Research and Development
• Collaborators: LifeQ
• Investigators: Principal Investigator: Arash Harzand, MD, Atlanta VA Medical and Rehab Center, Decatur, GA

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2021
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026

Study Registration Dates

• First Submitted: May 11, 2021
• First Submitted That Met QC Criteria: May 11, 2021
• First Posted (Actual): May 17, 2021

Study Record Updates

• Last Update Posted (Actual): April 21, 2026
• Last Update Submitted That Met QC Criteria: April 15, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Telemedicine; Peripheral artery disease; Mobile health
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Peripheral Vascular Diseases; Peripheral Arterial Disease; Organization and Administration; Health Services Administration; Personnel Management; Employee Performance Appraisal
• Other Study ID Numbers: E3546-W; IK2RX003546-02 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No